Second, because epigenetic re-activation of SOX2 expression via a pluripotency-specific enhancer can cause a subpopulation of tumor cells to dynamically acquire a CSC state, we evaluated the capacity of iadademstat to target the mammosphere-forming capacity -a well-accepted surrogate reporter of CSC activity- in established in vitro models bearing distinct mutational landscapes (i.e., BRCA1-mutated basal-like MDA-MB-436 and HER2 gene-amplified/luminal-B BT-474 cell lines) but sharing a common dependency on SOX2 expression to maintain their CSC phenotype. Here, SOX2 is linked to neoplasm.